Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

EU Extends Review of Teva, Cephalon Deal After Remedies

Don't Miss Out —
Follow us on:

Sept. 23 (Bloomberg) -- The European Commission extended its review of Teva Pharmaceutical Industries Ltd.’s bid for Cephalon Inc. after it was offered remedies to allay possible competition concerns over the deal.

The new deadline is Oct. 13, the commission said in a filing on its website today. It didn’t specify the remedies that were offered.

Link to Company News:{CEPH US <Equity> CN <GO>} Link to Company News:{TEVA IT <Equity> CN <GO>}

To contact the editor responsible for this story: Peter Chapman at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.